Natural History of Ocular GVHD

Bishop, Rachel

Abstract

All study participants have now completed one year of follow up and many have completed longer follow-up intervals. The data are currently being analyzed. A significant portion of the patients have been advised to use topical cyclosporine eye drops in response to changes in ocular indicators (symptoms, drop in Schirmers tear production, or worsening of surface dryness). We will attempt to identify any correlations between changes in patient symptoms, exam findings, and tear fluid biomarkers. We anticipate completing this analysis in the coming six months.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Eye Institute (NEI)
• Type: Investigator-Initiated Intramural Research Projects (ZIA)
• Project #: 1ZIAEY000512-05
• Application #: 9362405
• Support Year: 5
• Fiscal Year: 2016

Institution

• Name: U.S. National Eye Institute

Publications

Brooks, Brian P; Thompson, Amy H; Bishop, Rachel J et al. (2013) Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage. Ophthalmology 120:1324-36

Baird, Kristin; Steinberg, Seth M; Grkovic, Lana et al. (2013) National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant 19:632-9

Wang, Yujuan; Marciano, Beatriz E; Shen, Defen et al. (2013) Molecular identification of bacterial DNA in the chorioretinal scars of chronic granulomatous disease. J Clin Immunol 33:917-24

Smith, Wendy M; Reddy, Madhu G; Hutcheson, Kelly A et al. (2012) Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect 2:149-52

Sibley, Cailin H; Plass, Nikki; Snow, Joseph et al. (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64:2375-86